Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| SB Syntax BioCompany profile Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine | $14.4M | Series A+Series A | Biotech | United States | Investors | |
| PB Portal BiotechnologiesCompany profile Builds universal infrastructure for cell engineering across drug discovery and cell therapy Builds universal infrastructure for cell engineering across drug discovery and cell therapy | $9M | Undisclosed | Biotech | United States | Investors | |
| G GeroCompany profile Uses physics-based AI and longitudinal human data to discover drugs targeting aging and age-related diseases Uses physics-based AI and longitudinal human data to discover drugs targeting aging and age-related diseases | $17M | Undisclosed | Biotech | Singapore | Investors | |
| V Precision-fermented dairy proteins for food and nutrition brands. | €12.5M | EIC Accelerator blended-finance awardUndisclosed | Biotech, Foodtech | Netherlands | Investors | |
| TB Triveni BioCompany profile Develops novel antibody treatments for immunological and inflammatory disorders Develops novel antibody treatments for immunological and inflammatory disorders | $65M | Series CSeries C+ | Biotech | United States | Investors | |
| PL Pramaana LabsCompany profile Builds formal verification tools ensuring AI reliability in law, drug discovery, and tax prep Builds formal verification tools ensuring AI reliability in law, drug discovery, and tax prep | $27M | Seed | Biotech, Enterprise software | United States | Investors | |
| VT Develops next-generation therapies for migraine prevention | $46M | Series A | Biotech | United States | Investors | |
| SB Spot BiosystemsCompany profile Develops non-viral gene therapy using extracellular vesicle delivery platform for genetic medicines Develops non-viral gene therapy using extracellular vesicle delivery platform for genetic medicines | $40M | Series B | Biotech | United States | Investors | |
| E EmmecellCompany profile Develops magnetic cell delivery technologies for treating corneal and other ophthalmic diseases Develops magnetic cell delivery technologies for treating corneal and other ophthalmic diseases | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| D DioseveCompany profile Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden | $7M | Series A+Series A | Biotech | Japan | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.